Colgate-Palmolive Company filings document a global consumer-products issuer with NYSE-listed common stock and registered debt securities. The company's 8-K reports cover earnings releases, the Strategic Growth and Productivity Program, reportable operating segment realignments, senior-note activity, debt-listing changes and governance events such as director elections and officer succession.
Proxy materials describe board elections, executive compensation, shareholder voting matters and strategic priorities tied to growth, efficiency and cash flow. The filings also identify registered securities, including common stock and multiple note series, and provide formal records for shareholder meetings, compensation arrangements and changes affecting listed note classes.
Colgate-Palmolive Co. (CL) EVP and Controller Malcolm Gregory sold 4,100 common shares on November 10, 2026, at $97.97 per share. He directly held 10,061 shares after the sale. A separate holding entry lists 8,700 shares held indirectly by the issuer’s 401(k) Plan Trustee.
Colgate-Palmolive (CL) director Lorrie M. Norrington exercised options covering 4,170 shares on November 5, 2026, at an exercise price of $71.56 per share, acquired 4,170 common shares and sold 4,170 shares at $99.3101 per share. A portion of the sale proceeds was delivered to Colgate-Palmolive to pay the option exercise price. The reported balance for the exercised options after the transaction was 0 shares.
Colgate-Palmolive (CL) Chairman, President & CEO Noel R. Wallace sold 20,000 common shares on November 5, 2026, at a weighted average price of $100.2581 per share. The shares were sold in multiple transactions at prices ranging from $100.01 to $100.51, inclusive. He held 359,700 shares directly after the sale. The report also lists indirect holdings of 55,173 shares by the issuer’s 401(k) plan trustee, 52,000 shares by a spouse trust and 335 shares by a trust.
Colgate-Palmolive (CL) COO Panagiotis Tsourapas exercised 19,938 stock options on November 4, 2026, at a $76.41 exercise price, acquiring 19,938 common shares. Tsourapas sold 19,938 shares the same day at a weighted average price of $98.7415; sale prices ranged from $98.585 to $98.97. A portion of the sale proceeds was delivered to the issuer for payment of the exercise price and related tax withholding.
The reported post-transaction option balance was 0. Separate indirect common-stock holdings were 4,645 shares by the issuer's 401(k) Plan Trustee and 67,237 shares by a trust; the trust amount includes 2,336 shares previously reported as directly beneficially owned.
Colgate-Palmolive Chief Growth Officer John Hazlin exercised 23,376 stock options on November 4, 2026, at $77.04 per share, acquiring 23,376 common shares, and sold 23,376 shares that day at a weighted average price of $99.1479 per share. Sale prices ranged from $98.93 to $99.29; part of the proceeds went to the issuer for the exercise price and related tax withholding. The report lists 5,544 shares held indirectly by the issuer's 401(k) Plan Trustee, and no Rule 10b5-1 plan is reported.
Colgate-Palmolive Co. officer Lorrie M. Norrington reported a proposed sale of 4,170 common shares on November 5, 2026, in connection with an employee stock-option exercise. The listed aggregate market value is $414,123.12, and Merrill Lynch is identified as the broker for the broker-assisted cashless exercise.
Colgate-Palmolive Co. officer Noel Wallace reported a proposed sale of 20,000 common shares through Merrill Lynch, with an aggregate market value of $2,005,162.84 and an approximate sale date of November 5, 2026. The notice lists the shares as coming from restricted stock unit awards: 8,508 shares vested on October 2, 2024, and 11,492 shares vested on February 13, 2025. It also reports two prior sales by Noel Wallace: 161,021 shares on August 4, 2026, and 161,021 shares on August 5, 2026.
Colgate-Palmolive officer Panagiotis Tsourapas reported a proposed sale of 19,938 common shares, with an approximate sale date of November 4, 2026. The shares are described in connection with an employee stock-option exercise through a broker-assisted cashless exercise. The proposed shares are listed at an aggregate market value of $1,968,709.79.
Colgate-Palmolive Co. officer John Hazlin reported an intended sale of 23,376 common shares, with an aggregate market value of $2,317,683.03 and an approximate sale date of November 4, 2026. The notice lists the shares as obtained through exercise of employee stock options in a broker-assisted cashless exercise.
Colgate-Palmolive (CL) reported third-quarter 2026 net sales of $5.369 billion, up 4.6% from the third quarter of 2025, and organic sales growth of 3.6%. Net income attributable to the company was $751 million versus $735 million; diluted earnings per share were $0.94 versus $0.91. GAAP operating profit was $1.088 billion, up 3%. Hill’s Pet Nutrition and Oral, Personal and Home Care sales rose 5.6% and 4.4%, respectively.
For the first nine months of 2026, net sales were $16.055 billion, up 6.0%, while GAAP operating profit declined 5% to $3.069 billion and net income attributable to the company was $2.090 billion versus $2.169 billion. The Strategic Growth and Productivity Program recorded $333 million in pre-tax charges during the nine months; cumulative pre-tax charges are estimated at $350 million to $550 million once initiatives are approved and implemented, with substantially all charges expected by December 31, 2028. Management expects softness across its categories through the balance of 2026.